Family enjoying their time together

Tuberculosis

South African cure rates have improved from 67.8% in 2008 to 75.9% in 2012. It is therefore not surprising that SA HAS THE 3RD HIGHEST BURDEN IN THE WORLD and those with the highest burden are India & China (these also have the highest population than South Africa)respectively.

There are 3 aspects to TB Treatment:

  • Drug Susceptible (DS) TB treatment
  • Drug Resistant (DR) i.e. Multi and Extensively drug resistant (MDR & XDR) TB treatment
  • Preventative TB treatment (prophylaxis)

The Sanofi TB portfolio addresses all of these aspects with its portfolio of 6 products:

  • Rifafour & Rifinah
  • Terivalidin, Pyrazide and Ethatyl
  • Norstan - Isoniazid

The Sanofi Tuberculosis offers a comprehensive portfolio of drugs that can assists South Africans with addressing:

Defaulting, Relapse, and re-activation with various tools to complement the product range such as:

  • Providing tools to ensure HCP are equipped to make dosing simple, explain side effects, and be aware of drug interaction
  • Sponsor tools to follow up on defaulters
  • Support and encourage HCP’s with tools to make implementation of IPT treatment simple but effective
  • Provide tools to assist with identification of high risk environments where prophylactic treatment is necessary
  • Educate HCP’s on HIV concomitant therapy

These TB drugs are manufactured locally in Waltloo, near Mamelodi and currently exports accounts for 7% of the volumes including, Zambia/Angola/Mozambique/ Botswana/Namibia and Kenya. Plans to supply to the rest of the world are under way.

Our TB medicine is manufactured locally in Waltloo, near Mamelodi and currently exports accounts for 7% of the volumes including, Zambia, Angola, Mozambique, Botswana, Namibia and Kenya. Plans to supply to the rest of the world are under way